Skip to content

Impact of combined CYP2C19/CYP2B6 phenotypes on sertraline dose-normalized concentration and antidepressant switching incidence: A retrospective cohort study in Chinese Han population.

Oct 2026 · Progress in Neuro-psychopharmacology and Biological Psychiatry · pp. 111975 · 0 citations · 23 references
Medicine

Abstract

Sertraline, a commonly used first-line antidepressant for major depressive disorder, is primarily metabolized by the polymorphic cytochrome P450 enzymes CYP2C19 and CYP2B6. This large-scale Chinese cohort study (N = 1070 patients; 1414 serum concentration measurements) evaluated whether incorporating CYP2B6 phenotype provides additional information beyond CYP2C19 phenotype in explaining interindividual variability in dose-normalized sertraline concentrations, and investigated associations between combined CYP2C19/CYP2B6 phenotypes and antidepressant switching within 1 year after the last therapeutic drug monitoring assessment. Patients were classified according to CYP2C19 and CYP2B6 metabolizer phenotypes as poor metabolizers (PMs), intermediate metabolizers (IMs), normal metabolizers (NMs), or rapid metabolizers (RMs), resulting in 16 combined phenotype groups, with CYP2C19 NM/CYP2B6 NM as the reference group. Eight phenotype groups had significantly higher model-estimated dose-normalized sertraline concentrations than the reference group. The largest observed fold difference was for CYP2C19 PM/CYP2B6 IMs (fold change, 2.11; 95% CI, 1.84-2.42; FDR-adjusted P < 0.001), whereas the smallest significant fold difference was observed for CYP2C19 NM/CYP2B6 IMs (fold change, 1.15; 95% CI, 1.06-1.26; FDR-adjusted P = 0.002). The combined CYP2C19/CYP2B6 model showed better fit than the CYP2C19-only model (likelihood ratio test χ2 = 28.6, df = 3, P < 0.001). The overall incidence of antidepressant switching was 19.9%. Switching was more frequent in CYP2C19 PM/CYP2B6 IMs (34.3%; OR, 3.33; 95% CI, 1.50-7.41; P = 0.003), CYP2C19 IM/CYP2B6 IMs (26.2%; OR, 2.32; 95% CI, 1.33-4.06; P = 0.003), and CYP2C19 NM/CYP2B6 IMs (25.0%; OR, 2.26; 95% CI, 1.26-4.03; P = 0.006). These findings indicate that incorporating CYP2B6 phenotype provides additional information beyond CYP2C19 phenotype for characterizing variability in dose-normalized sertraline concentrations and support prospective evaluation of combined pharmacogenetic approaches to sertraline dosing and therapeutic drug monitoring.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.